Helena Marcelino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Helena Marcelino has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Cecília Reis Alves Santos
University of Beira Interior
10 shared publications - Isabel Gonçalves
University of Beira Interior
9 shared publications - Ana Catarina Duarte
University of Beira Interior
6 shared publications - José Francisco Cascalheira
RISE-Health, Department of Medical Sciences, Faculty of Health Sciences, University of Beira Interior, 6200-506 Covilhã, Portugal
6 shared publications - Ana Raquel Costa
RISE-Health, Department of Medical Sciences, Faculty of Health Sciences, University of Beira Interior, 6200-506 Covilhã, Portugal
5 shared publications - Telma Quintela
RISE-Health, Department of Medical Sciences, Faculty of Health Sciences, University of Beira Interior, Av. Infante D. Henrique, 6200-506 Covilhã, Portugal
4 shared publications
Latest Publications
- Open Access
- 3 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (7) , 3262
Bitter Taste Signalling via TAS2R43 Enhances Temozolomide Efficacy in Glioblastoma Cells
Bitter taste receptors (TAS2Rs) are increasingly recognised as extraoral chemosensors that modulate diverse biological processes, including cancer cell behaviour and drug responsiveness. Many TAS2R ligands correspond to therapeutic compounds; however, their contribution to the response of brain tumours to chemotherapy remains unexplored. Here, we investigated whether the bitter taste signalling pathway is modulated by temozolomide (TMZ), the standard chemotherapeutic agent for glioblastoma, with an impact on treatment efficacy in glioblastoma cells. We show that TMZ elicits intracellular Ca2+ responses compatible with activation of G-protein-coupled receptor signalling and induces anti-proliferative and pro-apoptotic effects in multiple human glioblastoma cell lines. Pharmacological inhibition of bitter taste receptors, as well as genetic silencing of the taste transduction G protein GNAT3, significantly attenuated TMZ-induced cytotoxicity, suggesting that bitter taste signalling is involved in this process. In silico ligand prediction combined with receptor expression profiling identified TAS2R43 as a candidate modulator of these effects, and TAS2R43 knockdown markedly reduced TMZ-induced loss of cell viability and apoptosis. Moreover, TMZ enhanced intracellular accumulation of the ABC transporter substrate doxorubicin, suggesting modulation of multidrug efflux mechanisms. Collectively, our findings identify TAS2R43 as a potential biomarker that warrants further validation to improve responses to TMZ and other ABC transporter-limited anticancer drugs.
- 3 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (7) , 3262
Open AccessBitter Taste Signalling via TAS2R43 Enhances Temozolomide Efficacy in Glioblastoma Cells
Bitter taste receptors (TAS2Rs) are increasingly recognised as extraoral chemosensors that modulate diverse biological processes, including cancer cell behaviour and drug responsiveness. Many TAS2R ligands correspond to therapeutic compounds; however, their contribution to the response of brain tumours to chemotherapy remains unexplored. Here, we investigated whether the bitter taste signalling pathway is modulated by temozolomide (TMZ), the standard chemotherapeutic agent for glioblastoma, with an impact on treatment efficacy in glioblastoma cells. We show that TMZ elicits intracellular Ca2+ responses compatible with activation of G-protein-coupled receptor signalling and induces anti-proliferative and pro-apoptotic effects in multiple human glioblastoma cell lines. Pharmacological inhibition of bitter taste receptors, as well as genetic silencing of the taste transduction G protein GNAT3, significantly attenuated TMZ-induced cytotoxicity, suggesting that bitter taste signalling is involved in this process. In silico ligand prediction combined with receptor expression profiling identified TAS2R43 as a candidate modulator of these effects, and TAS2R43 knockdown markedly reduced TMZ-induced loss of cell viability and apoptosis. Moreover, TMZ enhanced intracellular accumulation of the ABC transporter substrate doxorubicin, suggesting modulation of multidrug efflux mechanisms. Collectively, our findings identify TAS2R43 as a potential biomarker that warrants further validation to improve responses to TMZ and other ABC transporter-limited anticancer drugs.
- Open Access
- 25 February 2026
- Published by MDPI AG in Preprints.org
Bitter Taste Signalling via TAS2R43 Enhances Temozolomide Efficacy in Glioblastoma Cells
Bitter taste receptors (TAS2Rs) are increasingly recognized as extraoral chemosensors that modulate diverse biological processes, including cancer cell behaviour and drug responsiveness. Many TAS2R ligands correspond to therapeutic compounds; however, their contribution to the response of brain tumours to chemotherapy remains unexplored. Here, we investigated whether the bitter taste signalling pathway is modulated by temozolomide (TMZ), the standard chemotherapeutic agent for glioblastoma, with an impact in treatment efficacy in glioblastoma cells. We show that TMZ elicits intracellular Ca²⁺ responses compatible with activation of GPCR signalling, and induces antiproliferative and pro-apoptotic effects in multiple human glioblastoma cell lines. Pharmacological inhibition of bitter taste receptors, as well as genetic silencing of the taste transduction G protein GNAT3, significantly attenuated TMZ-induced cytotoxicity, suggesting the involvement of bitter taste signalling in the process. In silico ligand prediction combined with receptor expression profiling identified TAS2R43 as a candidate mediator of these effects, and TAS2R43 knockdown markedly reduced TMZ-induced loss of cell viability, and apoptosis. Moreover, TMZ enhanced intracellular accumulation of the ABC transporter substrate doxorubicin, suggesting modulation of multidrug efflux mechanisms. Collectively, our findings identify TAS2R43 as a previously unrecognized modulator of glioblastoma responsiveness cells to TMZ and support a role for bitter taste signalling in shaping intracellular drug availability. These results highlight TAS2R43 as a potential biomarker and therapeutic leverage point to improve responses to TMZ and other ABC transporter-limited anticancer drugs.
- 25 February 2026
- Published by MDPI AG in Preprints.org
Open AccessBitter Taste Signalling via TAS2R43 Enhances Temozolomide Efficacy in Glioblastoma Cells
Bitter taste receptors (TAS2Rs) are increasingly recognized as extraoral chemosensors that modulate diverse biological processes, including cancer cell behaviour and drug responsiveness. Many TAS2R ligands correspond to therapeutic compounds; however, their contribution to the response of brain tumours to chemotherapy remains unexplored. Here, we investigated whether the bitter taste signalling pathway is modulated by temozolomide (TMZ), the standard chemotherapeutic agent for glioblastoma, with an impact in treatment efficacy in glioblastoma cells. We show that TMZ elicits intracellular Ca²⁺ responses compatible with activation of GPCR signalling, and induces antiproliferative and pro-apoptotic effects in multiple human glioblastoma cell lines. Pharmacological inhibition of bitter taste receptors, as well as genetic silencing of the taste transduction G protein GNAT3, significantly attenuated TMZ-induced cytotoxicity, suggesting the involvement of bitter taste signalling in the process. In silico ligand prediction combined with receptor expression profiling identified TAS2R43 as a candidate mediator of these effects, and TAS2R43 knockdown markedly reduced TMZ-induced loss of cell viability, and apoptosis. Moreover, TMZ enhanced intracellular accumulation of the ABC transporter substrate doxorubicin, suggesting modulation of multidrug efflux mechanisms. Collectively, our findings identify TAS2R43 as a previously unrecognized modulator of glioblastoma responsiveness cells to TMZ and support a role for bitter taste signalling in shaping intracellular drug availability. These results highlight TAS2R43 as a potential biomarker and therapeutic leverage point to improve responses to TMZ and other ABC transporter-limited anticancer drugs.
- Open Access
Glioblastoma cells taste temozolomide via TAS2R43
Bitter taste receptors (TAS2Rs) have a widespread expression in various extraoral organs where they detect the chemical composition of body fluids and trigger biological responses accordingly. Among the chemicals recognised by TAS2Rs there are natural and synthetic compounds including therapeutic drugs. We have shown that TAS2Rs are expressed in the blood-cerebrospinal fluid barrier where they regulate efflux transporters, thereby controlling the transport of compounds into the cerebrospinal fluid. More recently, we assessed the expression of these receptors in human glioblastoma cells, where 20 out of the 26 human TAS2Rs were identified. In this study, we investigated if temozolomide, the standard chemotherapy for glioblastoma, activates the bitter signalling pathway with impact in its therapeutic efficacy. Notably, we found that blocking the bitter taste signalling pathway significantly reduced the anti-proliferative and pro-apoptotic effects of temozolomide, and identified TAS2R43 as the receptor mediating these effects. We propose that upon ligand binding, TAS2R43 modulates multidrug resistance proteins (MDRs) activity, facilitating temozolomide entrance into glioblastoma cells. These findings underscore the importance of the taste transduction pathway in evaluating the chemical composition of the glioblastoma microenvironment. Furthermore, our data suggest that TAS2R43 could serve as a biomarker for the efficacy of temozolomide and other drugs that are substrates of MDRs.
Open AccessGlioblastoma cells taste temozolomide via TAS2R43
Bitter taste receptors (TAS2Rs) have a widespread expression in various extraoral organs where they detect the chemical composition of body fluids and trigger biological responses accordingly. Among the chemicals recognised by TAS2Rs there are natural and synthetic compounds including therapeutic drugs. We have shown that TAS2Rs are expressed in the blood-cerebrospinal fluid barrier where they regulate efflux transporters, thereby controlling the transport of compounds into the cerebrospinal fluid. More recently, we assessed the expression of these receptors in human glioblastoma cells, where 20 out of the 26 human TAS2Rs were identified. In this study, we investigated if temozolomide, the standard chemotherapy for glioblastoma, activates the bitter signalling pathway with impact in its therapeutic efficacy. Notably, we found that blocking the bitter taste signalling pathway significantly reduced the anti-proliferative and pro-apoptotic effects of temozolomide, and identified TAS2R43 as the receptor mediating these effects. We propose that upon ligand binding, TAS2R43 modulates multidrug resistance proteins (MDRs) activity, facilitating temozolomide entrance into glioblastoma cells. These findings underscore the importance of the taste transduction pathway in evaluating the chemical composition of the glioblastoma microenvironment. Furthermore, our data suggest that TAS2R43 could serve as a biomarker for the efficacy of temozolomide and other drugs that are substrates of MDRs.
- Open Access
Taste receptors’ profiling in glioblastoma
Glioblastoma is the most common and aggressive form of primary brain cancer. Despite significant progress in the development of promising therapeutic agents, cancer-targeting therapies often fail to achieve effective concentrations in the brain, limiting their therapeutic efficacy. As such, a deeper understanding of how glioblastoma tumours interact with their microenvironment and assess the chemical composition therein can reveal novel therapeutic strategies. Recent studies have highlighted the critical role of taste receptors, particularly bitter taste receptors (TAS2Rs) and their ligands in cancer progression and metastasis. Activation of TAS2Rs by both natural and synthetic compounds has been associated with drug resistance, apoptosis, and the proliferation of malignant tumours. The sweet taste receptor TAS1R2/TAS1R3, or the umami receptor TAS1R1/TAS1R3, as recognised sensors of glucose levels and aminoacids, respectively, are also of interest in the context of cancer metabolism. In this study, we investigated the expression and function of TAS2Rs, TAS1R2/TAS1R3 and TAS1R1/TAS1R3 and all the taste signalling pathway machinery in glioblastoma. Our findings demonstrate that TAS1R2/TAS1R3, TAS1R1/TAS1R3, and 20 out of the 26 human TAS2Rs are present and active in glioblastoma cells, with expression differences in glioblastoma cells and human tumours. The expression of such a large number of members of this family of receptors, highlight the significance of the taste transduction pathway in this form of brain cancer, where these receptors might be essential for the crosstalk between glioblastoma and its microenvironment.
Open AccessTaste receptors’ profiling in glioblastoma
Glioblastoma is the most common and aggressive form of primary brain cancer. Despite significant progress in the development of promising therapeutic agents, cancer-targeting therapies often fail to achieve effective concentrations in the brain, limiting their therapeutic efficacy. As such, a deeper understanding of how glioblastoma tumours interact with their microenvironment and assess the chemical composition therein can reveal novel therapeutic strategies. Recent studies have highlighted the critical role of taste receptors, particularly bitter taste receptors (TAS2Rs) and their ligands in cancer progression and metastasis. Activation of TAS2Rs by both natural and synthetic compounds has been associated with drug resistance, apoptosis, and the proliferation of malignant tumours. The sweet taste receptor TAS1R2/TAS1R3, or the umami receptor TAS1R1/TAS1R3, as recognised sensors of glucose levels and aminoacids, respectively, are also of interest in the context of cancer metabolism. In this study, we investigated the expression and function of TAS2Rs, TAS1R2/TAS1R3 and TAS1R1/TAS1R3 and all the taste signalling pathway machinery in glioblastoma. Our findings demonstrate that TAS1R2/TAS1R3, TAS1R1/TAS1R3, and 20 out of the 26 human TAS2Rs are present and active in glioblastoma cells, with expression differences in glioblastoma cells and human tumours. The expression of such a large number of members of this family of receptors, highlight the significance of the taste transduction pathway in this form of brain cancer, where these receptors might be essential for the crosstalk between glioblastoma and its microenvironment.
- Open Access
- 20 December 2022
- Published by Springer Nature in Environmental Science and Pollution Research
- Vol. 30 (10) , 27682
Correction to: Effects of bisphenol A on human umbilical arteries
- 20 December 2022
- Published by Springer Nature in Environmental Science and Pollution Research
- Vol. 30 (10) , 27682
Open AccessCorrection to: Effects of bisphenol A on human umbilical arteries
- 16 November 2022
- Published by Springer Nature in Environmental Science and Pollution Research
- Vol. 30 (10) , 27670-27681
Effects of bisphenol A on human umbilical arteries
Bisphenol A (BPA) is an endocrine-disrupting chemical widely used in the plastics industry, including food container, toys, and medical equipment. We analyzed the effect of BPA in human umbilical artery contractility and expression of some proteins modulating this function, such as ionic channels and proteins involved in the cGMP pathway. Using standard organ bath technique, rings of human umbilical arteries without endothelium were contracted by 5-HT (1 μM) and histamine (10 μM) and the effect of different concentrations of BPA (1 nM–100 μM) was analyzed. The results showed that BPA is a vasodilator of these arteries in a concentration-dependent way. Besides, qPCR studies on human umbilical smooth muscle cells (HUSMC) allowed to analyze the effects of BPA on gene expression. Thus, 12-h exposition to BPA induced reduction of expression of L-type calcium channels (LTCC), alpha subunit of BKCa channels, and Kvβ1 and Kvβ3 from Kv channels. BPA also decreased the expression of soluble guanylate cyclase (sGC) and natriuretic peptide receptor type A (NPRA), meanwhile increasing that of PKG, proteins involved in vasodilation of human umbilical arteries (HUA) by cGMP. Further studies will be necessary to increase knowledge about the implications of these changes induced by BPA exposure. Graphical Abstract
- 16 November 2022
- Published by Springer Nature in Environmental Science and Pollution Research
- Vol. 30 (10) , 27670-27681
Effects of bisphenol A on human umbilical arteries
Bisphenol A (BPA) is an endocrine-disrupting chemical widely used in the plastics industry, including food container, toys, and medical equipment. We analyzed the effect of BPA in human umbilical artery contractility and expression of some proteins modulating this function, such as ionic channels and proteins involved in the cGMP pathway. Using standard organ bath technique, rings of human umbilical arteries without endothelium were contracted by 5-HT (1 μM) and histamine (10 μM) and the effect of different concentrations of BPA (1 nM–100 μM) was analyzed. The results showed that BPA is a vasodilator of these arteries in a concentration-dependent way. Besides, qPCR studies on human umbilical smooth muscle cells (HUSMC) allowed to analyze the effects of BPA on gene expression. Thus, 12-h exposition to BPA induced reduction of expression of L-type calcium channels (LTCC), alpha subunit of BKCa channels, and Kvβ1 and Kvβ3 from Kv channels. BPA also decreased the expression of soluble guanylate cyclase (sGC) and natriuretic peptide receptor type A (NPRA), meanwhile increasing that of PKG, proteins involved in vasodilation of human umbilical arteries (HUA) by cGMP. Further studies will be necessary to increase knowledge about the implications of these changes induced by BPA exposure. Graphical Abstract
- 1 June 2020
- Published by Elsevier in European Journal of Pharmacology
- Vol. 876, 173055
The effects of cannabinoids on glioblastoma growth: A systematic review with meta-analysis of animal model studies
- 1 June 2020
- Published by Elsevier in European Journal of Pharmacology
- Vol. 876, 173055
The effects of cannabinoids on glioblastoma growth: A systematic review with meta-analysis of animal model studies
- Open Access
- 23 December 2019
- Published by Wiley in Journal of Neurochemistry
- Vol. 153 (4) , 455-467
Adenosine inhibits human astrocyte proliferation independently of adenosine receptor activation
Brain adenosine concentrations can reach micromolar concentrations in stressful situations such as stroke, neurodegenerative diseases or hypoxic regions of brain tumours. Adenosine can act by receptor‐independent mechanism by reversing the reaction catalysed by S‐adenosylhomocysteine (SAH) hydrolase, leading to SAH accumulation and inhibition of S‐adenosylmethionine (SAM)‐dependent methyltransferases. Astrocytes are essential in maintaining brain homeostasis but their pathological activation and uncontrolled proliferation plays a role in neurodegeneration and glioma. Adenosine can affect cell proliferation, but the effect of increased adenosine concentration on proliferation of astrocytes is not clarified and was addressed in present work.Human astrocytes (HA) were treated for 3 days with test drugs. Cell proliferation/viability was assessed by the 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyl tetrazolium assay and by cell counting. Cell death was evaluated by assessing lactate dehydrogenase release and by western blot analysis of αII‐Spectrin cleavage. 30 µM‐Adenosine caused a 40% ± 3% (p < .05, n = 5) reduction in cell proliferation/viability, an effect reversed by 2U/ml‐adenosine deaminase, but unchanged in the presence of antagonists of any of the adenosine receptors. Adenosine alone did not induce cell death. 100 µM‐Homocysteine alone caused 16% ± 3% (p < .05) decrease in HA proliferation. Combined action of adenosine and homocysteine decreased HA proliferation by 76% ± 4%, an effect higher (p < .05) than the sum of the effects of adenosine and homocysteine alone (56% ± 5%). The inhibitory effect of adenosine on HA proliferation/viability was mimicked by two adenosine kinase inhibitors and attenuated in the presence of folate (100 µM) or SAM (50‐100 µM). The results suggest that adenosine reduces HA proliferation by a receptor‐independent mechanism probably involving reversal of SAH hydrolase‐catalysed reaction. image
- 23 December 2019
- Published by Wiley in Journal of Neurochemistry
- Vol. 153 (4) , 455-467
Open AccessAdenosine inhibits human astrocyte proliferation independently of adenosine receptor activation
Brain adenosine concentrations can reach micromolar concentrations in stressful situations such as stroke, neurodegenerative diseases or hypoxic regions of brain tumours. Adenosine can act by receptor‐independent mechanism by reversing the reaction catalysed by S‐adenosylhomocysteine (SAH) hydrolase, leading to SAH accumulation and inhibition of S‐adenosylmethionine (SAM)‐dependent methyltransferases. Astrocytes are essential in maintaining brain homeostasis but their pathological activation and uncontrolled proliferation plays a role in neurodegeneration and glioma. Adenosine can affect cell proliferation, but the effect of increased adenosine concentration on proliferation of astrocytes is not clarified and was addressed in present work.Human astrocytes (HA) were treated for 3 days with test drugs. Cell proliferation/viability was assessed by the 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyl tetrazolium assay and by cell counting. Cell death was evaluated by assessing lactate dehydrogenase release and by western blot analysis of αII‐Spectrin cleavage. 30 µM‐Adenosine caused a 40% ± 3% (p < .05, n = 5) reduction in cell proliferation/viability, an effect reversed by 2U/ml‐adenosine deaminase, but unchanged in the presence of antagonists of any of the adenosine receptors. Adenosine alone did not induce cell death. 100 µM‐Homocysteine alone caused 16% ± 3% (p < .05) decrease in HA proliferation. Combined action of adenosine and homocysteine decreased HA proliferation by 76% ± 4%, an effect higher (p < .05) than the sum of the effects of adenosine and homocysteine alone (56% ± 5%). The inhibitory effect of adenosine on HA proliferation/viability was mimicked by two adenosine kinase inhibitors and attenuated in the presence of folate (100 µM) or SAM (50‐100 µM). The results suggest that adenosine reduces HA proliferation by a receptor‐independent mechanism probably involving reversal of SAH hydrolase‐catalysed reaction. image
- 1 August 2018
- Published by Elsevier in Toxicology in Vitro
- Vol. 50, 210-216
Tributyltin role on the serotonin and histamine receptors in human umbilical artery
- 1 August 2018
- Published by Elsevier in Toxicology in Vitro
- Vol. 50, 210-216
Tributyltin role on the serotonin and histamine receptors in human umbilical artery
- 19 August 2016
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 28 (9)
Sex Hormones Protect Against Amyloid‐β Induced Oxidative Stress in the Choroid Plexus Cell Line Z310
The choroid plexus (CP) epithelium is a unique structure in the brain that forms an interface between the peripheral blood on the basal side and the cerebrospinal fluid (CSF) on the apical side. It is a relevant source of many polypeptides secreted to the CSF with neuroprotective functions and also participates in the elimination and detoxification of brain metabolites, such as β‐amyloid (Aβ) removal from the CSF through transporter‐mediated influx. The CP is also a target tissue for sex hormones (SHs) that have recognised neuroprotective effects against a variety of insults, including Aβ toxicity and oxidative stress in the central nervous system. The present study aimed to understand how SHs modulate Aβ‐induced oxidative stress in a CP cell line (Z310 cell line) by analysing the effects of Aβ1–42 on oxidative stress, mitochondrial function and apoptosis, as well as by assessing how 17β‐oestradiol (E2) and 5α‐dihydrotestosterone (DHT) modulated these effects and the cellular uptake of Aβ1–42 by CP cells. Our findings show that E2 and DHT treatment reduce Aβ1–42‐induced oxidative stress and the internalisation of Aβ1–42 by CP epithelial cells, highlighting the importance of considering the background of SHs and therefore sex‐related differences in Aβ metabolism and clearance by CP cells.
- 19 August 2016
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 28 (9)
Sex Hormones Protect Against Amyloid‐β Induced Oxidative Stress in the Choroid Plexus Cell Line Z310
The choroid plexus (CP) epithelium is a unique structure in the brain that forms an interface between the peripheral blood on the basal side and the cerebrospinal fluid (CSF) on the apical side. It is a relevant source of many polypeptides secreted to the CSF with neuroprotective functions and also participates in the elimination and detoxification of brain metabolites, such as β‐amyloid (Aβ) removal from the CSF through transporter‐mediated influx. The CP is also a target tissue for sex hormones (SHs) that have recognised neuroprotective effects against a variety of insults, including Aβ toxicity and oxidative stress in the central nervous system. The present study aimed to understand how SHs modulate Aβ‐induced oxidative stress in a CP cell line (Z310 cell line) by analysing the effects of Aβ1–42 on oxidative stress, mitochondrial function and apoptosis, as well as by assessing how 17β‐oestradiol (E2) and 5α‐dihydrotestosterone (DHT) modulated these effects and the cellular uptake of Aβ1–42 by CP cells. Our findings show that E2 and DHT treatment reduce Aβ1–42‐induced oxidative stress and the internalisation of Aβ1–42 by CP epithelial cells, highlighting the importance of considering the background of SHs and therefore sex‐related differences in Aβ metabolism and clearance by CP cells.